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Abstract
Background
Zika virus (ZIKV) was first isolated in Africa; decades later, caused large outbreaks in the
Pacific, and is considered endemic in Asia. We aim to describe ZIKV disease epidemiology
outside the Americas, the importance of travelers as sentinels of disease transmission, and
discrepancies in travel advisories from major international health organizations.
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Methods and findings
This descriptive analysis using GeoSentinel Surveillance Network records involves sixty-
four travel and tropical medicine clinics in 29 countries. Ill returned travelers with a confirmed
or probable diagnosis of ZIKV disease acquired in Africa, Asia and the Pacific seen between
1 January 2012 and 31 December 2016 are included, and the frequencies of demographic,
trip, and diagnostic characteristics described. ZIKV was acquired in Asia (18), the Pacific
(10) and Africa (1). For five countries (Indonesia, Philippines, Thailand, Vietnam, Camer-
oon), GeoSentinel patients were sentinel markers of recent Zika activity. Additionally, the
first confirmed ZIKV infection acquired in Kiribati was reported to GeoSentinel (2015), and a
probable case was reported from Timor Leste (April 2016), representing the only case
known to date. Review of Zika situation updates from major international health authorities
for country risk classifications shows heterogeneity in ZIKV country travel advisories.
Conclusions
Travelers are integral to the global spread of ZIKV, serving as sentinel markers of disease
activity. Although GeoSentinel data are collected by specialized clinics and do not capture
all imported cases, we show that surveillance of imported infections by returned travelers
augments local surveillance system data regarding ZIKV epidemiology and can assist with
risk categorization by international authorities. However, travel advisories are variable due
to risk uncertainties.
Introduction
Zika virus (ZIKV) made global headlines in 2015 when Brazil identified the first cases of con-
firmed transmission. The alarming association with congenital abnormalities triggered the
World Health Organization (WHO) to declare a public health emergency of international con-
cern on 1 February 2016 [1]. Whereas significant attention has focused on the Americas and
travel-associated cases exported from the Americas, including exportation of cases reported to
GeoSentinel [2], ZIKV was first isolated from a rhesus macaque in 1947 in the Zika Forest in
Uganda [3, 4] and was responsible for large outbreaks in 2007 in the Pacific Islands of Yap
(Federated States of Micronesia) and in 2013 in French Polynesia [5, 6]. Based on serological
studies, ZIKV has been endemic in certain regions of Africa and of Asia for over 50 years [3,
7–15] and has been silently circulating in West Africa for over 20 years [16], although limita-
tions in serological testing and potential cross-reactivity with other flaviviruses hinder reliable
interpretation.
ZIKV is now widely distributed throughout the tropics and sub-tropics, with 75 countries
and territories reporting evidence of vector-borne ZIKV transmission between 2015 and 2016
including: three in West and Central Africa (Cape Verde, Guinea-Bissau, Gabon), 13 in the
Pacific (American Samoa, Fiji, Marshall Islands, Micronesia, Palau, Samoa, Tonga, New Cale-
donia, Cook Islands, French Polynesia, Papua New Guinea, Solomon Islands, Vanuatu), and
10 in Asia (Indonesia, Maldives, Thailand, Bangladesh, Singapore, Philippines, Vietnam, Cam-
bodia, Malaysia, Lao People’s Democratic Republic) [17]. In Africa and Asia-Pacific regions,
an estimated 26 billion people live in areas with competent mosquito vectors and climatic
conditions are suitable for local transmission of ZIKV [18].
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Despite recent advances in knowledge and research regarding ZIKV, a general lack of dis-
ease awareness prior to the current outbreak, misdiagnoses due to the clinical similarity of
ZIKV infections with other infectious diseases, and limited access to diagnostic testing have
resulted in many unresolved questions regarding the distribution and transmission risks out-
side the Americas. There is also uncertainty regarding the impact of different strains and the
potential for obstetric and neurological complications, particularly in Asia and Africa. To date,
all reported Pacific and American Zika isolates and associated neurologic or microcephaly
complications have been attributed to the expansion of the Asian lineage [19–21], but cases of
microcephaly have been investigated in Guinea-Bissau and Angola, where the current out-
break is caused by the African lineage [17]. While it is thought that Asian and African ZIKV
strains differ in their abilities to infect cells of the central nervous system and to cause neurode-
velopmental problems [22], residual uncertainties hinder accurate risk assessment and con-
struction of clear, evidence-based recommendations. Nevertheless, international authorities
must provide guidance as a key element of the outbreak response, including advice for interna-
tional travelers for their own self-protection and in order to limit risks of secondary local
transmission on return from travel to areas with the Aedes spp. vector.
To develop a broader understanding of the extent of ZIKV among international travelers
from Africa, Asia and the Pacific and the role travelers play in identifying areas of endemicity,
we analyzed ZIKV infections reported by the GeoSentinel Surveillance Network and juxta-
posed these cases with a review of the published literature and web-based reports of ZIKV
cases in select countries outside the Americas. We also examined the level and timing of advi-
sories issued by four major international health authorities: WHO, European Center for Dis-
ease Control and Prevention (ECDC), US Centers for Disease Control and Prevention (CDC),
and Public Health England’s National Travel Health Network and Centre (NaTHNaC).
Methods
GeoSentinel is a global surveillance network established in 1995 (www.istm.org/geosentinel),
currently comprising 64 specialized travel and tropical medicine clinics in 29 countries, the
majority being in Europe, America, Australia or New Zealand. To be eligible for inclusion in
the GeoSentinel database, patients must have crossed an international border and sought med-
ical advice at a GeoSentinel clinic for a presumed travel-related illness. Data collected include:
demographic information, travel data, reason for most recent travel, inpatient or outpatient
status, travel duration, and time between the onset of symptoms and presentation at a GeoSen-
tinel clinic. Diagnoses are taken from a list of>500 standardized diagnostic codes. Clinics col-
lect de-identified data on ill travelers for whom they have provided clinical care using a
standard form, and report these data to a centralized database [23]. The institutional review
board officer at CDC’s National Center for Emerging and Zoonotic Infectious Diseases classi-
fies the data collection protocol as public health surveillance and not human subjects research.
Data extraction and disease diagnostic criteria
Data on patients diagnosed with ZIKV infection acquired in Africa, Asia or the Pacific (regions
defined as per Harvey et al [23]) acquired between 1 January 2012 and 31 December 2016 were
extracted from the GeoSentinel database. Sites contributing patient data provided supplemen-
tal information including clinical complications and results of diagnostic testing, which was
based on local clinician preferences and availability of methods (serology, plaque reduction
neutralization test [PRNT], and/or molecular testing including polymerase chain reaction
[PCR] and sequencing). Using a modified version of the US Council of State and Territory
Epidemiologists (CSTE) case definitions [24] (S1 Table), two clinicians (DHH, MPG)
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independently classified each patient as confirmed or probable, and discussed discrepancies to
reach a final determination. We examined demographic information, itinerary details and rea-
son for travel for each case; country of exposure was based on travel itinerary and relevant
incubation periods, with cases excluded if the exposure country could not be ascertained. Geo-
Sentinel cases were considered to be sentinel events (index cases) if no other known human
case had been reported in web-based or published literature for at least 2 years prior. Data
were managed in Microsoft Excel, with reporting of descriptive statistics.
PubMed, ProMED, International SOS reports, WHO situation reports, ECDC situation
reports, the CDC website and online news reports were searched (minimum of two co-
authors) using the search criteria “Zika” and “Africa or Asia or Pacific”, or “Zika” and each
individual country name in these three regions to identify locally acquired or exported cases.
Data on the status and timing of international travel advisories were tabulated following a
search of the relevant authorities’ websites, including review of weekly situation reports where
relevant [17, 25–27].
Results
The first case of ZIKV infection reported to GeoSentinel acquired outside the Americas
occurred in a traveler in May 2012 (infection acquired in Indonesia). Since then, two subse-
quent cases were reported in 2013, five cases in 2014, three in 2015, and 18 cases in 2016 (total
of 29 cases, Table 1). Eighteen cases were acquired in Asia, ten in the Pacific, and one in Africa
(Fig 1). Twenty-two cases are considered confirmed based on PCR (16 cases), PRNT (3 cases)
or serology (5 cases), and seven cases are considered probable. Sixteen cases occurred among
males and thirteen among females, one of whom was in the second trimester of pregnancy at
the time of exposure and has subsequently given birth to a healthy infant. The median age was
40 years (range: 20–66 years). Fifteen cases occurred among tourists, four among migrant
workers, three were travelers visiting friends and relatives, three were missionary workers, two
were business travelers, one occurred in a military personnel and one case in an expatriate.
Where relevant, the median trip duration to country of exposure was 17 days (range: 6–335
days) and the median time from symptom onset to clinic presentation was 5 days (range: 1–49
days). Twenty-two patients were managed as outpatients. The diagnosis was made at GeoSen-
tinel sites in Asia (8 cases), Western Europe (12 cases), North America (6 cases), Australia/
New Zealand (2 cases), and the Middle East (1 case).
Comparative temporal reporting of GeoSentinel cases with locally reported cases and
exported non- GeoSentinel cases in travelers is shown (Figs 2–4, S2 Table). Eight GeoSentinel
cases occurred in travelers who were diagnosed with ZIKV infection following a visit to an
area early during a recognized outbreak (within first 4–6 weeks: one case in American Samoa
[January 2016], three cases in French Polynesia [December 2013 to January 2014] [29, 31], two
cases in Tonga [March 2016], one case in the Maldives [June 2016] [30, 33], and one case in
Palau [November 2016]). Five additional cases reported in Singapore similarly presented early
after initial outbreak recognition [August to September 2016]. For an additional 7 countries,
GeoSentinel cases were the sentinel markers of ZIKV activity, three of which are reported here
for the first time (Table 1) [28, 30, 32, 34–36].
• Sentinel case from Indonesia, exported by an Australian traveler in 2012 [32]. Apart from
sero-survey data from the 1970s and 1980s (S2 Table), this was the first case from Indonesia
(PCR-positive).
• Sentinel case from the Philippines in 2014, exported by a German traveler. This was the first
Zika case in the Philippines since 2012 (not reported previously).
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Table 1. Demographic, itinerary, and laboratory characteristics of GeoSentinel Zika patients from Africa, Asia, and the Pacific.
Country of
acquisition
Demographics Travel Dates Type of travel
and
presentation
Diagnosis Other results Designation Comments
American
Samoa
26 yo M Travel: 18 to 25 Jan
2016. Illness onset:
26 Jan 2016
Business travel.
Seen after travel
as outpatient in
US
ZIKV PCR neg but
IgM and PRNT pos
from specimen
taken 29 Feb 2016
Dengue IgM
equivocal;
dengue PCR
and PRNT neg
C Occurred coincident with
earliest cases recognized
in American Samoa (1st
reports emerged in Jan
2016)
Cameroon 58 yo M Travel: 23 Feb to 23
Mar 2015. Illness
onset: 1 April 2015
Missionary. Seen
after travel as
inpatient in
Belgium
ZIKV IgM pos,
ZIKV PRNT >640
from specimen
taken on day 7
after illness onset
Dengue
serology, NS1
Ag and PCR
neg
P Only reported case of
ZIKV in Cameroon since
2010 (also reported in
[28]) (incidental
retrospective diagnosis
while evaluating ZIKV
serological diagnostics),
but note that probable
case only. GeoSentinel
index case
French
Polynesia
(city of
Papeete)
32 yo F Travel: Mid Nov to 5
Dec 2013.Illness
onset: 9 Dec 2013
Tourist. Seen
after travel as
inpatient in
Norway
PCR pos from
blood specimen
taken on day 4
after illness onset
(ZIKV IgM and IgG
initially neg, but
convalescent
serum 1 year later
was IgM and IgG
pos)
Dengue IgM
and NS1 Ag
neg
C 1st reports of French
Polynesian outbreak
occurred in Oct/Nov
2013, so not a sentinel
event but occurred very
early in the outbreak
(reported in [29] and [30],
ProMED Archive number
20140303.2309965)
French
Polynesia
65 yo M Travel: 27 Dec
2013 to 12 Jan
2014. Illness onset:
7 Jan 2014
Tourist. Seen
after travel as
outpatient in US
ZIKV IgM (and
IgG) and ZIKV
PRNT pos from
specimen taken on
day 7 after illness
onset
Dengue IgM
also pos but
dengue PRNT
neg
P Case coincided with early
reports of local outbreak
(Nov 2013). Imported into
US (likely included in
[31]), but note that
probable case only
French
Polynesia
55 yo M Travel: 26 Dec
2013 to 7 Jan 2014.
Illness onset: 12
Jan 2014
Traveling in
military. Seen
after travel as
outpatient in
France
ZIKV IgM and IgG
pos from specimen
taken on day 16
after illness onset
Dengue
serology, NS1
Ag and PCR
neg
P Case coincided with early
reports of local outbreak
reports (Nov 2013), but
note probable case only
French
Polynesia
40 yo M Travel: 16 Oct to 3
Nov 2016.
Asymptomatic
(screened as wife
wanting to
conceive). Clinic
visit date: 7 Dec
2016
Tourist. Seen
after travel as
outpatient in
France
Zika IgM pos
(ELISA) and PRNT
pos on blood
specimen taken 7
Dec 2016, but
PCR from blood
and semen neg
Dengue
serology not
done
P French Polynesia not
considered as having
ongoing ZIKV activity in
late 2016, but note that
probable case only
Indonesia
(Jakarta)
52 yo F 14 to 25 May 2012.
Illness onset 25
May 2012
Tourist. Seen
after travel as
outpatient in
Australia
PCR pos for
flavivirus from
blood on specimen
taken on day 4
after illness onset
sequencing
identified ZIKV
Dengue IgM
and IgG low
pos, NS1 Ag
neg, dengue
PCR neg
C Had been reports of
positive serosurveys for
ZIKV in 1970s and 1980s,
but this case (reported in
[32]) was the 1st proven
case from Indonesia.
GeoSentinel index case
Kiribati
(South
Tarawa)
29 yo F Travel: Mid -Jan
2015 to 23 April
2015. Illness onset:
25 April 2016
Missionary. Seen
after travel as
outpatient in New
Zealand
PCR pos on blood
from specimen
taken on day 5
after illness onset
Dengue PCR
neg
C 1st reported case of ZIKV
ever to be reported from
Kiribati. GeoSentinel
index case
(Continued )
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Table 1. (Continued)
Country of
acquisition
Demographics Travel Dates Type of travel
and
presentation
Diagnosis Other results Designation Comments
Maldives 34 yo M Travel: 3 to 13 June
2016. Illness onset:
16 June 2016
Tourist. Seen
after travel as
outpatient in
Germany
ZIKV PCR pos
from blood
specimens taken
22 June, 14 July
and 26 July and
from urine
specimen taken 22
July 2016; ZIKV
IgM and IgG also
pos (IIFAT)
Dengue IgM
and PCR neg
C There are 2 earlier
reports of exportation in
travelers (June 2015 and
Feb 2016) but 1st reports
of locally acquired
infection occurred in June
2016, so this case
imported into Germany
coincident with earliest
cases recognized in
Maldives [30, 33]
ProMED Archive Number
20161001.4529740)
Micronesia
(Kosrae)
24 yo F Travel: 1 to 19 Sep
2016. Patient was
asymptomatic but
presented on return
from travel (20 Sep
2016) as was 18
weeks pregnant.
Normal obstetric
US at 36 weeks
(January 2017),
declined
amniocentesis,
gave birth to
healthy-appearing
baby.
Migrant born in
Micronesia, living
in the USA, who
travelled to
Micronesia as a
VFR, and was
seen after travel
as an outpatient
in US
ZIKV PCR pos)
and IgM pos on
blood specimen
taken 20 Sep 2016
Dengue IgM
and PCR neg
C Initial reports of outbreak
in Kosrae in Jan 2016,
with ongoing outbreak
activity since
(approximately 20 cases
per month from Sep to
Oct 2016)
Palau 36 yo F Travel: 26 Sep to 7
Oct 2016. Illness
onset: 6 Oct 2016
Tourist. Seen
after travel as
outpatient in
Netherlands
ZIKV IgM and IgG
pos on blood
specimens taken
on day 8 after
illness onset, and
ZIKV PCR neg on
urine
Dengue
serology (IgM
and IgG) and
NS1 Ag neg
P The first report from
Palau of a locally
acquired case was on 7
Nov 2016. Symptom
onset of this case was
one month prior, but
diagnosis made
coincident with earliest
cases recognized in
Palau. Note that probable
case only
Philippines 20 yo M Travel: Jan 2014 to
20 Dec 2014.
Illness onset: 1 Dec
2014
Missionary. Seen
after travel as
outpatient in
Germany
ZIKV IgM pos 1:
160, ZIKV IgG pos
1: 20480 (IIFT)
from blood taken 3
weeks after illness
onset
Dengue IgM
pos 1: 160,
dengue IgG
1:1280. Dengue
tests neg when
tested in the
Philippines
during acute
illness
C Positive serosurveys for
ZIKV in 1950s in
Philippines, and 1st
locally acquired case was
reported in 2012, but this
was 1st case known to
have been acquired from
Philippines since 2012
(S2 Table). GeoSentinel
index case
Singapore 43 yo M Travel: 9 Aug to >3
Sep 2016. Illness
onset: 1 Sep 2016
Tourist from
China. Seen
during travel
while in
Singapore as
inpatient
ZIKV PCR pos on
blood and urine on
day 2 after illness
onset
Dengue IgM
and NS1 Ag
neg
C 5 GeoSentinel cases
between 28 Aug and 5
Sep 2016 (4 in migrant
workers), coinciding with
early peak of outbreak
(Continued)
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Table 1. (Continued)
Country of
acquisition
Demographics Travel Dates Type of travel
and
presentation
Diagnosis Other results Designation Comments
Singapore—
locally
acquired
25 yo M Illness onset: 30
Aug 2016
Migrant worker
from
Bangladesh.
Inpatient in
Singapore
ZIKV PCR pos on
blood and urine on
day 3 after illness
onset
Dengue IgM
and NS1 Ag
neg
C
Singapore—
locally
acquired
33 yo F Illness onset: 2 Sep
2016
Migrant worker
from Malaysia.
Inpatient in
Singapore
ZIKV PCR pos (in
house assay) on
blood and urine on
day 3 after illness
onset
Dengue IgM
and NS1 Ag
neg
C
Presumed
acquisition
in Singapore
30 yo M Travel: Visited
Malaysia (Ipoh)
from 23 to 25 Aug
2016. Illness onset:
27 Aug 2016
Migrant worker
from Malaysia.
Inpatient in
Singapore
ZIKV PCR pos on
blood and urine on
day 1 after illness
onset
Dengue IgM
and NS1 Ag
neg
C Presumed to have been
acquired in Singapore,
although by late Aug/
early Sep 2016 cases
were being reported from
Malaysia, which is
notable given travel to
Malaysia late Aug 2016
[30] (ProMED Archive
number
20160908.4475100)
Singapore—
locally
acquired
49 yo M Illness onset: 24
Aug 2016
Migrant worker
from Malaysia.
Inpatient in
Singapore
ZIKV PCR pos on
blood and urine on
day 5 after illness
onset
Dengue IgM
and NS1 Ag
neg
C
Thailand 63 yo F Travel: 20 Jan to 5
Feb 2013. Illness
onset: 11 Feb 2013
Tourist. Seen
after travel as
outpatient in
Canada
PCR pos from
blood and urine
specimen taken on
days 1 and 4 after
illness onset. ZIKV
IgM equivocal, and
PRNT pos 15
March (CDC)
Dengue IgM
pos but PCR
neg
C Were positive
serosurveys from
Thailand prior to 2012,
but this case (reported in
[34]) emerged prior to
recent reports of
autochthonous
transmission (also
reported in [30], ProMED
Archive Number
20130529.1744108).
GeoSentinel index
case. Subsequent
retrospective recognition
of sporadic cases (3
locally acquired cases
from March 2012, 2
sporadic cases reported
in 2013 and 2 cases in
2014 [S2 Table])
Thailand
(Koh Samui)
41 yo M Travel: 25 to 31 July
2014. Illness onset:
2 Aug 2014
Tourist. Seen
after travel as
outpatient in
Japan
ZIKV PCR pos
from blood
specimen taken on
day 2 after illness
onset, and from
urine taken on day
5; ZIKV IgM also
pos (day 5 and day
11 after illness
onset)
Dengue IgM
pos, NS1 Ag
neg
C 2nd GeoSentinel case
exported from Thailand
(reported in [30, 35],
ProMED Archive Number
20140823.2716731).
Occurred concurrent with
early emerging reports of
local ZIKV in Thailand
(Continued)
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Table 1. (Continued)
Country of
acquisition
Demographics Travel Dates Type of travel
and
presentation
Diagnosis Other results Designation Comments
Thailand 25 yo F Travel: 1 to 31
August 2014.
Illness onset: 26
Aug 2014
Tourist. Seen
after travel as
outpatient in
Germany
ZIKV IgM neg but
IgG pos > 1:20840
from specimen
taken on day 8
after illness onset
Dengue IgM
neg, dengue
IgG pos 1: 80,
and NS1 Ag
neg
C Case not previously
reported
Thailand 37 yo M Travel: 31 July to 18
Aug 2016. Illness
onset: unknown.
Clinic visit date 23
Aug 2016
Tourist. Seen
after travel as
outpatient in Italy
ZIKV IgM and IgG
neg on 23 Aug and
9 Sep 2016, but
PCR pos from
urine specimen
taken 23 Aug 2016
No dengue
serology
available
C Case occurred during
known low-level
circulation of ZIKV in
Thailand. Note that PCR
was pos despite neg
serology for ZIKV
Thailand 51 yo F Travel: 5 July to 28
July 2016. Illness
onset: 30 Jul. Clinic
visit date 9 Aug
2016
Tourist. Seen
after travel as
outpatient in
Spain
ZIKV IgG pos on
day 10 after illness
onset and on 8
Sep 2016
Dengue IgM
neg and PCR
neg
C Case occurred during
known low-level
circulation of ZIKV in
Thailand
Thailand 54 yo F Travel: 5 July to 28
July 2016. Clinic
visit date 9 Aug
2016
Tourist. Seen
after travel as
outpatient in
Spain
Zika IgM and and
IgG pos 9 Aug and
8 Sep 2016
Dengue IgM
pos and PCR
neg
P Case occurred during
known low-level
circulation of ZIKV in
Thailand. Probable case
only
Timor Leste 29 yo M Travel: 14 to 28 Apr
2016 (brief stop-
overs in Bali,
Indonesia and in
Singapore). Illness
onset: 8 May 2016
TouristSeen after
travel as
outpatient in
Germany. (Note:
patient presented
on 26 June, 2
months after the
acute illness
when feeling
well)
ZIKV IgM pos (IIFT
and confirmatory
ELISA weakly pos
1.01 [neg <0.8]).
ZIKV IgG pos (IIFT
pos and
confirmatory
ELISA pos 1.12
[neg <0.8]) from
blood specimen
taken 26 June
2016
Dengue IgM
and NS1 Ag
neg, dengue
IgG pos
(1:10240)
P This is the only report of
ZIKV from Timor Leste,
imported into Germany,
but note that probable
case only. Probable
GeoSentinel index case
Tonga
(Nakolo)
66 yo M Travel: 18 Feb to 3
March 2016. Illness
onset: 2 March
2016
VFR. Seen after
travel as
outpatient in US
ZIKV PCR neg but
IgM and
confirmatory
PRNT pos, titre
>20480 on blood
specimen taken on
day 5 after illness
onset
Dengue PCR
neg, IgM pos
but confirmatory
PRNT neg (titre
320)
C 1st cases reported Jan
2016 and 1st exported
case in a traveler to
Europe reported 10–16
Jan, so these 2 cases
imported (husband and
wife) occurred relatively
early during the local
outbreak
Tonga
(Nakolo)
60 yo F Travel: 18 Feb to 3
March 2016. Illness
onset: 2 March
2016
VFR. Seen after
travel as
outpatient in US
(wife of patient
above)
ZIKV PCR neg but
IgM and
confirmatory
PRNT pos, titre
2460 on blood
specimen taken on
day 5 after illness
onset
Dengue PCR
neg, IgM pos
but confirmatory
PRNT neg (titre
<20)
C As above
Vietnam (Ho
Chi Minh
City)
61 yo M Travel: 10 to 23 Dec
2015. Illness onset:
25 Dec 2015
Tourist. Seen
after travel as
outpatient in
Israel
ZIKV IgM and IgG
(and ZIKV PCR
were pos on blood
taken on day 10
after illness onset
Dengue capture
IgM, dengue
IgG indirect and
NS1Ag were
neg
C Case (reported in [30,
36], ProMED Archive
number
20160317.4102468) was
1st report of ZIKV from
Vietnam since 1954.
GeoSentinel index case
(Continued )
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• Sentinel, PCR-positive case from Thailand, exported by a Canadian traveler in 2013 [34]
(previously serological evidence only from 1950s [S2 Table]).
• Sentinel case from Vietnam, exported by an Israeli traveler in December 2015 [36]. Apart
from sero-survey data from the 1950s (S2 Table), this was the first case from Vietnam (PCR-
positive).
• Only known case acquired in Cameroon since 2010, exported by a Belgian traveler in 2015
[28].
• First known case reported from Kiribati, exported by a traveler to New Zealand in 2015 (not
previously reported).
• Only known case reported from Timor Leste, exported by a German traveler in April 2016
(not previously reported, albeit probable case only).
Comparisons of risk classifications and travel advisories issued by the four major interna-
tional authorities are shown in Table 2, and are temporally associated with Zika cases as shown
in Figs 2–4.
Discussion
Travelers are key to the global spread of ZIKV [37]. This report emphasizes the vital role travel-
ers play as sentinels, the complementary information systematic traveler surveillance provides
to local surveillance data, and the role travelers play in understanding the geographic extent of
virus circulation in areas that may otherwise be undetected because of often-asymptomatic
infections, limited surveillance, sub-optimal diagnostics, and co-circulation of other arbovi-
ruses [2, 7, 36, 41]. When returning home to countries where competent vectors are present,
Table 1. (Continued)
Country of
acquisition
Demographics Travel Dates Type of travel
and
presentation
Diagnosis Other results Designation Comments
Vietnam 49 yo F Travel: German
woman living in
Vietnam, traveled to
Singapore Aug 16
to 18, and Aug 21 to
22 2016, and then
traveled to Japan
on 8 Sep and
presented on 9 Sep
2016. Illness onset:
6 Sep 2016
Business travel.
Seen during
travel as an
outpatient in
Japan
ZIKV PCR pos on
urine specimen
taken on day 6
after illness onset
(neg results from
blood on days 3
and 6 after illness
onset), , ZIKV IgM
pos
Dengue IgM
and NS1 Ag
neg
C Case reported in [30]
(ProMED Archive number
20160915.4491053)
Vietnam 37 yo F Illness onset: 19
Dec 2016
Expatriate living
in Ho Chi Minh
City. Seen as an
outpatient in
Vietnam
ZIKV PCR
(positive on urine
on day 1 after
illness onset
Dengue IgM
and NS1 Ag
neg
C Case occurred during
known low-level
circulation of ZIKV in
Vietnam
Note: no traveller reported any neurological complications. F: female; M: male; yo: year old; ZIKV: Zika virus; pos: positive; neg: negative; PCR: polymerase
chain reaction, PRNT: plaque reduction neutralization test; ELISA: enzyme-linked immunosorbent assay; IIFT: indirect immunofluorescence test; C:
confirmed, P: probable. Designation of C versus P adapted from [2, 24] (See S1 Table); VFR: visiting friends and relatives
https://doi.org/10.1371/journal.pone.0185689.t001
Zika beyond the Americas
PLOS ONE | https://doi.org/10.1371/journal.pone.0185689 October 3, 2017 9 / 23
travelers can introduce ZIKV into new areas, thereby also providing a source for propagation
and circulation of infection among the local population [18, 42].
The GeoSentinel ZIKV case acquired in Indonesia in May 2012 was among the first spo-
radic cases reported in a traveler [32, 36]. In countries with lower access to reliable diagnostic
testing, local surveillance systems may have limited capacity to detect endemic ZIKV activity,
and patient assessment in well-resourced sites facilitates high-level diagnostic support from
reference laboratories. Limited awareness of ZIKV may have resulted in earlier missed cases,
but since then travelers have been involved in many additional importations globally, with
exportations from Asia, the Pacific and Africa highlighted here since GeoSentinel cases from
the Americas were recently reported [2].
The role travel-associated cases, including those reported by GeoSentinel, have played as
indicator of local ZIKV infections has varied in different regions. ZIKV in South America, the
Caribbean and the Pacific led to clinically apparent local outbreaks, with exported cases in
travelers also reported [2]. GeoSentinel data cannot be used to infer risk of infection since
there is non-uniformity in the likelihood of presenting to a specialized GeoSentinel clinic
according to geographical and other factors, but as of the end of 2016, over 400 cases of ZIKV
had been reported to GeoSentinel following travel to the Americas, compared to the 29 cases
reported here from other regions. Comprehensive seroprevalence and strain cross-reactivity
studies are lacking, but there appears to be lower epidemic potential for ZIKV in most African
and Asian countries, with fewer recognized local cases and exported cases not infrequently
triggering recognition of ZIKV circulation [16]. For Africa, exported cases in travelers have
been reported from Senegal [43] and Cape Verde [33], in addition to the GeoSentinel case
from Cameroon [28]. For Asia, we are aware of only a single country (Malaysia) that has
reported exported cases but for which there is not a confirmed GeoSentinel case. Moreover,
GeoSentinel cases served as the first identification of recent ZIKV activity in all Asian coun-
tries with known circulation except for the Maldives and Singapore, highlighting the impor-
tance of travelers in understanding ZIKV epidemiology. The lower epidemic potential
particularly in Asia is presumed to be because of long-standing lower-level endemic ZIKV
Fig 1. Place of exposure and place of diagnosis (arrows) of GeoSentinel Zika patients from Africa
(green dot), Asia (red dots), and the Pacific (blue dots)—Circular arrows indicate cases in
international travelers who contracted Zika while abroad and were diagnosed in the country of
exposure while traveling. Linear arrows indicate cases in international travelers who contracted Zika while
abroad and had their diagnosis confirmed on returning to their home country.—Base map is available free of
charge from http://www.histgeo.ac-aix-marseille.fr/ancien_site/carto/.
https://doi.org/10.1371/journal.pone.0185689.g001
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circulation, prior exposure to a broad range of flaviviruses and prior immunization with Japa-
nese encephalitis vaccine which potentially provides cross-protection to ZIKV [44]. These fac-
tors which may have resulted in higher background ZIKV seroprevalence, greater levels of
population-wide immunity, fewer clinical manifestations, and greater difficulties with serolog-
ical confirmation [7].
During 2016, there were significant differences in risk categorizations and in interpretation
of data by the four major international authorities, possibly underpinned by political factors,
which created marked variability in country stratifications and non-uniformity in both timing
and presence of travel advisories (Figs 2–4, S2 Table). While travel advisories generally pre-
sume that the presence of endemic disease and a partially immune population pose less risk to
travelers than travel during a recognized outbreak, the impact on transmission risks to non-
immune visiting travelers from varying levels of herd immunity in local communities remains
uncertain. In March 2017, country classifications for ZIKV epidemiology were modified by a
Fig 2. Temporal association of endemic and exported cases with travel notices by international authorities for selected countries in Africa.
https://doi.org/10.1371/journal.pone.0185689.g002
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working group formed by the WHO, CDC and ECDC in order to achieve greater harmoniza-
tion, with resulting revisions leading to four main categories (Category 1: new or re-introduc-
tion and ongoing transmission; Category 2: past or ongoing transmission but not in the new
or re-introduction phase; Category 3: interrupted transmission with potential for future
Fig 3. Temporal association of endemic and exported cases with travel notices by international authorities for selected countries in Asia.
https://doi.org/10.1371/journal.pone.0185689.g003
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Fig 4. Temporal association of endemic and exported cases with travel notices by international authorities for selected
countries in the Pacific.
https://doi.org/10.1371/journal.pone.0185689.g004
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transmission; Category 4: competent vector exists but no known past or current transmission,
Table 2 [39]). However, each organization handles risk mitigation differently: CDC refers to
the four country classification designations by WHO [45], but lists only two broad transmis-
sion risk levels: “risk present” and “risk absent” [25]. ECDC has the same four Zika virus epide-
miology classifications as WHO, but differentiates the WHO Category 2 countries with
current outbreaks, and also shows Category 4 subgroups [40]. NaTHNaC has four risk catego-
ries, with risk levels ranked into high, medium, low, or very low risk [27] (Table 2). Further-
more, there is non-uniformity in correlation of country classifications with travel advisories.
CDC, ECDC and WHO all make recommendations for pregnant women to avoid travel to
countries with documented ZIKV transmission in Categories 1 and 2. CDC further recom-
mends avoiding travel to Category 4a subgroup countries. ECDC differentially grades the risk
both for Category 2 countries (endemic countries versus endemic countries with documented
“intense transmission”), and for the two Category 4 countries (Category 4a subgroup countries
versus 4b). WHO provides no ZIKV warning for those travelling to countries in the Category
4 sub-group. Correlation with NaTHNac categories is somewhat variable. The result is a com-
plex, inconsistent set of recommendations where assessment of the travel risks to pregnant
travelers for some specific destinations may be listed anywhere from no risk, caution only or
high risk for which travel should be avoided depending on the source of information sought.
For example, for Kenya and Tanzania, CDC recommends avoidance of travel, whereas other
agencies have no risk warning (as of September 2017).
In addition to uncertainties on ZIKV epidemiology, case definitions vary. The current
CSTE definitions [24] are more detailed than WHO definitions [46], but two aspects of these
definitions that merit attention. First, neither addresses anti-Zika IgG (likely because of assay
unavailability in the United States), so in our modified case definitions we have added mention
of IgG to both probable and confirmed categories (S1 Table). The more challenging limitation
relates to interpretation of cases, such as the importation from Cameroon, for which dengue
serology was negative (as were NS1 Ag and PCR), yet Zika IgM and confirmatory PRNT were
positive. When routine tests for dengue serology are negative and Zika serology is positive,
many centers would not perform PRNT. Furthermore, cases with positive PCR and negative
serology are now recognized (such as the GeoSentinel case exported from Thailand to Italy,
Table 1), leading to additional complexities with defining optimal testing algorithms. Updated
guidelines for global definitions which take into account varying scenarios, optimal testing
according to timing of presentation relative to exposure, and assay availability in different
countries are needed.
Characteristics of ZIKV transmission can often be best determined in travelers returning
from endemic areas, for which the period of exposure may be more easily determined than
among local populations. Sexual transmission is best assessed in non-endemic settings where
there are no competent mosquito vectors; notably the first detection of sexual transmission
occurred in a traveler from Africa [43]. Additionally, investigation of returned travelers has
ascertained the maximum reported period between symptom onset and sexual transmission
(34–41 days) [47], the longest duration of shedding of infectious virus particles (69 days) [48],
and the maximum duration of detection of Zika genomic sequences in semen (188 days) [49].
These data underpin current international guidelines recommendations for avoidance of preg-
nancy for at least 6 months after potential exposure for males and at least 8 weeks for females.
A limitation of this descriptive report is that surveillance data captured by GeoSentinel
include only cases seen at specialized clinics, mostly in developed countries; they do not cap-
ture all imported cases and may not be representative of all global travelers. Moreover, Geo-
Sentinel is unable to provide denominator data or absolute risk information. However,
GeoSentinel’s deliberate focus to collate data from highly specialized clinics underscores the
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utility of assessing disease in travelers as a mechanism for identifying geographic areas where
emerging diseases may be occurring. Another limitation is that we cannot entirely exclude
diagnosis or (unpublished) recognition of additional earlier ZIKV cases, thereby potentially
overstating the value of the GeoSentinel reports as index cases. However, given our extensive
review of published data and media sources, we nevertheless assert that GeoSentinel reports
provide important additive case information.
In summary, many uncertainties in ZIKV epidemiology, transmission and risk of adverse
outcomes remain, and consensus on diagnostic and definition issues is needed. We have
described ZIKV cases among travelers visiting Africa, Asia and the Pacific, highlighted the
integral role of travelers as sentinels of ZIKV infection, shown that GeoSentinel assists in the
identification of these travelers, and have contextualized GeoSentinel cases with other reported
(locally acquired or exported) cases. We have also demonstrated the differential impact of trav-
elers as sentinels in Asia, which likely relates to the lower epidemic potential due to prior flavi-
virus circulation among the population of this region. Our findings also detail the basis for
non-uniformity in travel advisories issued by the four major international authorities. The
presence of variable travel advisories may create confusion for health practitioners and indi-
vidual travelers when determining risks, and the small but non-zero potential for causing dev-
astating fetal outcomes must be discussed. Traveler consultations need to account for overall
ZIKV risk assessment, residual risk uncertainties and individual risk tolerance.
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